DelveInsight’s “Generalized Pustular Psoriasis – Market Insight, Epidemiology, And Market Forecast – 2034″ report offers an in-depth understanding of the Generalized Pustular Psoriasis, historical and forecasted epidemiology as well as the Generalized Pustular Psoriasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Some of the key facts of the Generalized Pustular Psoriasis Market Report:

• According to DelveInsight, the market for Generalized Pustular Psoriasis in the 7MM is expected to experience notable growth during the forecast period from 2020 to 2034.

• Females are more likely to present with Generalized Pustular Psoriasis than males, according to the findings.

• In the US, the prevalent cases of Pustular Psoriasis were estimated to be approximately 240K in 2023.

• Generalized Pustular Psoriasis patients are often categorized into two groups: mild-to-moderate and moderate-to-severe psoriasis. In the US, the highest number of severity-specific cases in 2023 were found in the moderate-to-severe type.

• In March 2024, the US FDA expanded the approval for Boehringer’s SPEVIGO to include the treatment of Generalized Pustular Psoriasis in both adults and pediatric patients aged 12 and above (weighing ≥40 kg). Previously, it was approved for treatment only during acute flares in adults, and this expanded approval addresses both acute and chronic treatment needs for these patients.

• Additional treatments for Generalized Pustular Psoriasis include IL-36 pathway inhibitors, IL-17 inhibitors, IL-23 inhibitors, TNF-α inhibitors, retinoids, calcineurin inhibitors, anti-folate therapy, and PDE4 inhibitors.

• Emerging drugs in development for Generalized Pustular Psoriasis include TAK-279, Imsidolimab, JNJ-2113, and others.

• Key companies involved in the Generalized Pustular Psoriasis market include AnaptysBio, Takeda, Johnson & Johnson, and others.

• The growing need for both acute and chronic treatments, along with the ongoing development of novel therapies, is expected to significantly drive the market growth.

To Know in detail about the Generalized Pustular Psoriasis market outlook, drug uptake, treatment scenario, and epidemiology trends, Click here: Generalized Pustular Psoriasis Market Forecast

Generalized Pustular Psoriasis Overview

Generalized Pustular Psoriasis (GPP) is a rare and severe form of psoriasis characterized by widespread sterile pustules on inflamed, erythematous skin. Unlike plaque psoriasis, GPP can present with systemic symptoms such as fever, chills, fatigue, and organ complications, making it a life-threatening condition if left untreated. The disease can occur in acute flare-ups or as a chronic condition with recurrent episodes.

The exact cause of GPP is not fully understood, but it is linked to genetic mutations, immune system dysregulation, and inflammatory cytokines, particularly interleukin-36 (IL-36). Triggers such as infections, stress, pregnancy, and withdrawal from corticosteroids can exacerbate the condition. Due to its severity and potential for complications like sepsis and multi-organ failure, early diagnosis and aggressive treatment are crucial.

Current treatment options for GPP include systemic therapies such as biologics (IL-36, IL-17, and IL-23 inhibitors), immunosuppressants, and supportive care for symptom management. With ongoing advancements in targeted therapies and increased awareness, the market for GPP treatment is expanding, improving patient outcomes and addressing the high unmet medical need.

Get a Free sample for the Generalized Pustular Psoriasis Market Report: https://www.delveinsight.com/report-store/generalized-pustular-psoriasis-market

Generalized Pustular Psoriasis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Generalized Pustular Psoriasis Epidemiology Segmentation:

The Generalized Pustular Psoriasis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by:

• Total Prevalent Cases of Psoriasis in the 7MM

• Total Prevalent Cases of Pustular Psoriasis in the 7MM

• Total Prevalent Cases of Generalized Pustular Psoriasis in the 7MM

• Gender-specific Diagnosed Prevalent Cases of Generalized Pustular Psoriasis in the 7MM

• Age-specific Diagnosed Prevalent Cases of Generalized Pustular Psoriasis in the 7MM

• Severity-specific Diagnosed Prevalent Cases of Generalized Pustular Psoriasis in the 7MM

Download the report to understand which factors are driving Generalized Pustular Psoriasis epidemiology trends @ Generalized Pustular Psoriasis Epidemiology Forecast

Generalized Pustular Psoriasis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Generalized Pustular Psoriasis market or expected to be launched during the study period. The analysis covers the Generalized Pustular Psoriasis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Generalized Pustular Psoriasis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Generalized Pustular Psoriasis Market Strengths

• The development of novel biologics, particularly IL-36 inhibitors, is revolutionizing GPP treatment, offering more effective and personalized therapeutic options.

• Growing investments in research and a surge in clinical trials for innovative drugs are expanding treatment possibilities and driving market growth.

Generalized Pustular Psoriasis Market Weaknesses

• Due to its rarity, GPP is often misdiagnosed or underdiagnosed, leading to treatment delays and increased risk of complications.

• Advanced biologic therapies can be expensive, limiting access for patients in low-income regions and posing reimbursement challenges in some healthcare systems.

Scope of the Generalized Pustular Psoriasis Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Generalized Pustular Psoriasis Therapies: TAK-279, Imsidolimab, JNJ-2113, and others.

• Key Generalized Pustular Psoriasis Companies: AnaptysBio, Takeda, Johnson & Johnson, and others.

• Generalized Pustular Psoriasis Therapeutic Assessment: Generalized Pustular Psoriasis currently marketed and Generalized Pustular Psoriasis emerging therapies

• Generalized Pustular Psoriasis Market Dynamics: Generalized Pustular Psoriasis market drivers and Generalized Pustular Psoriasis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Generalized Pustular Psoriasis Unmet Needs, KOL’s views, Analyst’s views, Generalized Pustular Psoriasis Market Access and Reimbursement

To learn more about the key players and advancements in the Generalized Pustular Psoriasis Treatment Landscape, visit the Generalized Pustular Psoriasis Market Analysis Report

Table of Contents

1. Generalized Pustular Psoriasis Market Report Introduction

2. Executive Summary for Generalized Pustular Psoriasis

3. SWOT analysis of Generalized Pustular Psoriasis

4. Generalized Pustular Psoriasis Patient Share (%) Overview at a Glance

5. Generalized Pustular Psoriasis Market Overview at a Glance

6. Generalized Pustular Psoriasis Disease Background and Overview

7. Generalized Pustular Psoriasis Epidemiology and Patient Population

8. Country-Specific Patient Population of Generalized Pustular Psoriasis

9. Generalized Pustular Psoriasis Current Treatment and Medical Practices

10. Generalized Pustular Psoriasis Unmet Needs

11. Generalized Pustular Psoriasis Emerging Therapies

12. Generalized Pustular Psoriasis Market Outlook

13. Country-Wise Generalized Pustular Psoriasis Market Analysis (2020–2034)

14. Generalized Pustular Psoriasis Market Access and Reimbursement of Therapies

15. Generalized Pustular Psoriasis Market Drivers

16. Generalized Pustular Psoriasis Market Barriers

17. Generalized Pustular Psoriasis Appendix

18. Generalized Pustular Psoriasis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/